Curetis Expands Geographic Presence with Entry into Northern African and Latin American Markets
- New Unyvero distribution partnerships in Egypt, Mexico, and Uruguay
- Contractual commitments for 45 Unyvero Systems
Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, August 07, 2018, 09:30 a.m. EDT – Curetis N.V. (the “Company” and together with its subsidiaries “Curetis“), a developer of next-level molecular diagnostic solutions, today announced exclusive distribution partnerships in Egypt, Mexico, and Uruguay with Future Horizon Scientific, Quimica Valaner S.A. de C.V., and Biko S.A., respectively. The signing of these agreements follows a systematic qualification process conducted by Curetis, which focused on identifying distributors that are experienced in commercializing innovative products for international molecular diagnostics companies.
Each of the three new distribution partners intends to commercialize all five Unyvero Application Cartridges that are currently CE-IVD-marked: HPN for pneumonia, ITI for implant and tissue infections, BCU for bloodstream infections, IAI for intra-abdominal infections, and UTI for urinary tract infections. To establish the installed base of Unyvero Analyzers required to run these cartridge-based tests, the partners have in total committed to purchasing a minimum of 45 Unyvero systems at Curetis’ distributor transfer prices over a three-year period. In addition, they have collectively committed to minimum purchases of several thousand Application Cartridges over the term of the agreements.
The agreements will allow Curetis to expand its commercial reach into countries in Northern Africa and Latin America. Initial commercialization activities are expected to begin in the fourth quarter of 2018, following product registrations in the respective countries. The process of registering Unyvero in each of these countries has been initiated following the execution of the respective agreements.
“We are excited to partner with Future Horizon Scientific, Quimica Valaner, and Biko as top-tier distributors that have built strong track records in working with companies like QIAGEN, Bio-Rad, Bruker, and GE Healthcare,” said Oliver Schacht, PhD, Chief Executive Officer of Curetis. “Egypt, Mexico, and Uruguay are important countries in the Northern African and Latin American healthcare markets. We anticipate that selling our products through partners in these markets will increasingly contribute to our revenue growth in the coming years. Within just a few months of joining the Company, our new Head of Global Commercial Partner Management, Eneko Goya, has not only negotiated and closed these three agreements, but has also generated a strong pipeline and a very healthy funnel of new distribution partnership opportunities, which we intend to drive to contract closures in the coming months.”
“Since its foundation, Quimica Valaner’s spirit has been the introduction of reliable and innovative diagnostic technologies to the Mexican market”, said Homero Hernandez, CEO of Quimica Valaner. “We are convinced that Curetis’ Unyvero solution will resolve important limitations in the diagnosis of infectious diseases in Mexico, creating a direct benefit for the quality-of-life of the Mexican population as well as a sustainable and successful business alliance between Quimica Valaner and Curetis.”
To-date, Curetis has signed 16 distribution partnerships covering 29 countries and is planning to expand its distribution network and commercial reach through further partnerships with suitably positioned distributors.
###
About Curetis
Curetis N.V.’s (Euronext: CURE) goal is to become a leading provider of innovative solutions for molecular microbiology diagnostics designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients.
Curetis’ Unyvero System is a versatile, fast and highly automated molecular diagnostic platform for easy-to-use, cartridge-based solutions for the comprehensive and rapid detection of pathogens and antimicrobial resistance markers in a range of severe infectious disease indications. Results are available within hours, a process that can take days or even weeks if performed with standard diagnostic procedures, thereby facilitating improved patient outcomes, stringent antibiotic stewardship and health-economic benefits. Unyvero in vitro diagnostic (IVD) products are marketed in Europe, the Middle East, Asia and the U.S.
Curetis’ wholly owned subsidiary Ares Genetics GmbH offers next-generation solutions for infectious disease diagnostics and therapeutics. The ARES Technology Platform combines what the Company believes to be the most comprehensive database worldwide on the genetics of antimicrobial resistances, ARESdb, with advanced bioinformatics and artificial intelligence.
For further information, please visit www.curetis.com and www.ares-genetics.com.
Legal Disclaimer
This document constitutes neither an offer to buy nor an offer to subscribe for securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This press release includes statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “intends,” “targets,” “may,” “will,” or “should” and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis’ actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Contact details
Curetis’ Contact Details
Curetis GmbH
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr@curetis.com or ir@curetis.com
www.curetis.com – www.unyvero.com
International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info(@)akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Lee Roth
lroth@theruthgroup.com
Tel. +1 646 536 7012
Attachment
